Group
anti-GITR mAb
Group Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Mechanism of Action | anti-GITR mAb |
| Drugs in group | BMS-986156 |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Theoretical immune synergy (↑effector T cells, ↓intratumoral Tregs), complementing RT-induced ICD (Cattaneo et al. Strahlentherapie und Onkologie 2026; Galassi et al Immunological Reviews 2024). Anticipated theoretical adverse events are immune-related (potentiated inflammation/irAEs) rather than DNA-level normal-tissue sensitization.
The data above refer to patients treated with anti-GITR mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Combination therapy data are available in the section below.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.